Creo Medical Group
CREO · AIM · Health Care · mcap £47m · 10.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Results | Unaudited interim results
H1-26 revenue up 45% to £3.2m; operating costs down 15%; company confident in 50-60% full year growth. |
−12.4% |
| 28 Jul 26 | Trading update | H1-26 Trading Update
H1-26 revenue up 45% to £3.2m; operating costs down 15%; on track for full year 50-60% growth guidance. |
+0.0% |
| 23 Jul 26 | MicroBlate™ Flex exceeds 100 clinical cases
MicroBlate Flex microwave ablation product exceeds 100 clinical cases across UK and European centres. |
−1.8% | |
| 06 Jul 26 | Award of Shares under Share Incentive Plan
Award of Shares under Share Incentive Plan and Director Dealings |
+0.0% | |
| 29 Jun 26 | AGM Statement
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, provides an update to shareholders ahead of its An |
+8.3% | |
| 23 Jun 26 | Appointment of Nominated Adviser /Corporate Broker
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces the appointment of Shore Capital and Cor |
+0.0% | |
| 22 May 26 | Fundraise | Result of Placing
Creo Medical raised £5.5 million via placing of 36.7 million shares at 15 pence each. |
+27.5% |
| 22 May 26 | Fundraise | Proposed Placing to raise approximately £5.5m
Creo Medical Group proposes £5.5m placing of 36.7m shares at 15p, with directors committing £2.15m. |
+27.5% |
| 22 May 26 | Results | FY25 Final Results
FY25 revenue grew 50% to £6.0m, operating loss reduced 38.5%, H2 momentum continuing into 2026. |
+27.5% |
| 22 May 26 | Proposed Sale of 49% Interest in Creo Medical SL
Creo Medical proposes to sell its 49% stake in Creo Medical SL to the subsidiary's CEO for cash at carrying value. |
+27.5% | |
| 07 May 26 | MicroBlate™ Fine commercial update
MicroBlate Fine reaches 50 clinical cases worldwide with first pancreatic lesion treatment in US. |
+5.2% | |
| 05 May 26 | SpydrBlade™ Flex used in novel BEAM procedures
SpydrBlade Flex used successfully in novel BEAM bariatric endoscopy procedures by leading US clinician. |
+1.0% | |
| 30 Apr 26 | KOL presentations on Creo Core Products at DDW
Key opinion leaders present validation studies of Creo's endoscopic devices at Digestive Disease Week conference. |
+6.1% | |
| 29 Apr 26 | UK private hospital use Speedboat for cancer case
The London Clinic becomes first UK private hospital to use Speedboat for early colorectal cancer treatment. |
+1.0% | |
| 22 Apr 26 | Trading update | Positive Q1 trading update
Q1 revenue growth of 60% year-on-year, at upper limit of expectations; FY26 guidance 40-60% growth confirmed. |
+3.9% |
| 16 Apr 26 | Disposal and outsourcing of manufacturing
Creo sells manufacturing operations to management buyout team as part of outsourcing strategy. |
+3.2% | |
| 24 Feb 26 | Appointment of Joint Corporate Broker
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces the appointment of Shore Capital Stockbr |
+1.5% | |
| 20 Jan 26 | Trading update | FY25 Trading Update
FY25 revenue grew 50% to £6.0m with underlying operating costs cut 20% and operating loss halved. |
−5.1% |
| 14 Jan 26 | Award of Shares under Share Incentive Plan
Award of Shares under Share Incentive Plan and Director Dealings |
−2.3% | |
| 27 Oct 25 | Notice of Capital Markets Day
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that, further to the announcement on 7 O |
+1.1% | |
| 07 Oct 25 | Capital Markets Day update
CMD to be rearranged to allow clinician case using Creo products to be completed |
+0.0% |
Company filings. Not investment advice.